Model-based projection of health and economic effects of screening for hepatitis C in Canada
Open Access
- 25 August 2017
- journal article
- Published by CMA Impact Inc. in CMAJ Open
- Vol. 5 (3) , E662-E672
Abstract
Background: Because most hepatitis C virus (HCV) infections are asymptomatic and often unrecognized, screening for hepatitis C has been proposed as a plausible public health strategy. We examined the health and economic consequences of a selective one-time hepatitis C screening program for specific populations in the context of current treatment patterns. Methods: We used a state-transition model to evaluate 2 general strategies: no screening, and screen and treat with direct-acting antiviral agents. We examined these strategies for 4 different target populations (scenarios): 1) asymptomatic people not at high risk for HCV infection, 2) immigrant populations with high prevalence, 3) a birth cohort of people aged 25-64 years and 4) a birth cohort of people aged 45-64 years of age. We obtained model data from the published literature and expert opinions. We used a payer perspective, a lifetime time horizon and a 5% discount rate. Results: Screening would prevent 49.7%, 57.4%, 64.1% and 49.6% of HCV-related deaths over the lifetime of the cohort for scenarios 1, 2, 3 and 4, respectively. Screening would produce incremental-cost-effectiveness ratios between $31 468/quality-adjusted life-year and $50 490/quality-adjusted life-year. Probabilistic sensitivity analyses indicated that the chance that screening would be cost-effective at $50 000 willingness-to-pay threshold was 39.5%, 63.2%, 58.4% and 58.1% for scenarios 1, 2, 3 and 4, respectively. Interpretation: Our analyses suggest that a one-time hepatitis C screening and treatment program in Canada is likely to be cost-effective for scenarios 2, 3 and 4. The screening programs we have evaluated would identify asymptomatic people with chronic HCV infection and would enable medical treatment to be offered if needed before the development of advanced liver disease.Keywords
This publication has 23 references indexed in Scilit:
- Mortality from treatable illnesses in marginally housed adults: a prospective cohort studyBMJ Open, 2015
- Cost-effectiveness of screening for hepatitis C in CanadaCanadian Medical Association Journal, 2015
- A Canadian screening program for hepatitis C: Is now the time?Canadian Medical Association Journal, 2013
- Current experience with applying the GRADE approach to public health interventions: an empirical studyBMC Public Health, 2013
- The NICE Cost-Effectiveness ThresholdPharmacoEconomics, 2008
- Peginterferon -2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological responseGut, 2005
- Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4Liver International, 2004
- Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990Medical Decision Making, 2004
- Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient PopulationJAMA, 2003
- Pretreatment Evaluation of Chronic Hepatitis CJAMA, 1998